| Bergstrom Eye And Laser Clinic | |
|
2601 University Dr S, Fargo, ND 58103-6025 | |
| (701) 235-5200 | |
| (701) 237-0927 |
| Full Name | Bergstrom Eye And Laser Clinic |
|---|---|
| Type | Facility |
| Speciality | Specialist |
| Location | 2601 University Dr S, Fargo, North Dakota |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801819826 | NPI | - | NPPES |
| 01068001 | Other | ND | BLUE CROSS OF ND |
| 33A70BE | Other | MN | COMPREHENSIVE CARE SERVIC |
| 33A70BE | Other | MN | BLUEPLUS OF MN |
| 12698 | Medicaid | ND | |
| 33A70BE | Other | MN | BLUE CROSS OF MN |
| 01068001 | Other | ND | BLUE CROSS FEDERAL |
| Provider Name | Lance K Bergstrom |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1578509733 PECOS PAC ID: 5092794735 Enrollment ID: I20100825000247 |
News Archive
Substituting deuterium for certain hydrogen atoms in molecules has been shown to enhance the metabolic properties of a number of drugs and provides a promising approach to the discovery and development of innovative drug products.
PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has been awarded two grants by the U.S. Government under the QTDP program to advance the development and commercialization of two theragnostic products: ADCC Therasight and Lupus Therasight. PIKAMAB applied for two grants, both of which qualified and received the maximum grant amounts totaling approximately $488,959.
Sanofi-aventis announced today results of a study which demonstrated that patients using Lantus® (insulin glargine [rDNA origin] injection) once-daily and Apidra® (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin. Two abstracts from this study were highlighted at the American Diabetes Association's 70th Annual Scientific Sessions (ADA).
Bad news about the economy could cause you to pack on the pounds, according to a new study published in Psychological Science, a journal of the Association for Psychological Science.
› Verified 3 days ago
| Provider Name | Tracie Malsom |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1720038441 PECOS PAC ID: 8628085750 Enrollment ID: I20131126001931 |
News Archive
Substituting deuterium for certain hydrogen atoms in molecules has been shown to enhance the metabolic properties of a number of drugs and provides a promising approach to the discovery and development of innovative drug products.
PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has been awarded two grants by the U.S. Government under the QTDP program to advance the development and commercialization of two theragnostic products: ADCC Therasight and Lupus Therasight. PIKAMAB applied for two grants, both of which qualified and received the maximum grant amounts totaling approximately $488,959.
Sanofi-aventis announced today results of a study which demonstrated that patients using Lantus® (insulin glargine [rDNA origin] injection) once-daily and Apidra® (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin. Two abstracts from this study were highlighted at the American Diabetes Association's 70th Annual Scientific Sessions (ADA).
Bad news about the economy could cause you to pack on the pounds, according to a new study published in Psychological Science, a journal of the Association for Psychological Science.
› Verified 3 days ago
| Provider Name | Matthew Stein |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1205501095 PECOS PAC ID: 6507261708 Enrollment ID: I20210826001498 |
News Archive
Substituting deuterium for certain hydrogen atoms in molecules has been shown to enhance the metabolic properties of a number of drugs and provides a promising approach to the discovery and development of innovative drug products.
PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has been awarded two grants by the U.S. Government under the QTDP program to advance the development and commercialization of two theragnostic products: ADCC Therasight and Lupus Therasight. PIKAMAB applied for two grants, both of which qualified and received the maximum grant amounts totaling approximately $488,959.
Sanofi-aventis announced today results of a study which demonstrated that patients using Lantus® (insulin glargine [rDNA origin] injection) once-daily and Apidra® (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin. Two abstracts from this study were highlighted at the American Diabetes Association's 70th Annual Scientific Sessions (ADA).
Bad news about the economy could cause you to pack on the pounds, according to a new study published in Psychological Science, a journal of the Association for Psychological Science.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bergstrom Eye And Laser Clinic 2601 University Dr S, Fargo, ND 58103-6025 Ph: (701) 235-5200 | Bergstrom Eye And Laser Clinic 2601 University Dr S, Fargo, ND 58103-6025 Ph: (701) 235-5200 |
News Archive
Substituting deuterium for certain hydrogen atoms in molecules has been shown to enhance the metabolic properties of a number of drugs and provides a promising approach to the discovery and development of innovative drug products.
PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has been awarded two grants by the U.S. Government under the QTDP program to advance the development and commercialization of two theragnostic products: ADCC Therasight and Lupus Therasight. PIKAMAB applied for two grants, both of which qualified and received the maximum grant amounts totaling approximately $488,959.
Sanofi-aventis announced today results of a study which demonstrated that patients using Lantus® (insulin glargine [rDNA origin] injection) once-daily and Apidra® (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin. Two abstracts from this study were highlighted at the American Diabetes Association's 70th Annual Scientific Sessions (ADA).
Bad news about the economy could cause you to pack on the pounds, according to a new study published in Psychological Science, a journal of the Association for Psychological Science.
› Verified 3 days ago